Want to join the conversation?
$GILD said that for 1Q16 it reported non-GAAP diluted EPS of $3.03 vs. $2.94 in 1Q15. Total revenues were $7.8Bil, up 3% YoverY and down 8% sequentially. Product sales were $7.7Bil, an increase of 4% YoverY and down 9% sequentially. The company said that it sees strong uptick of its newer single-tablet regimens, including Genvoya.
$JNJ down 2% in pre-market trading. Earnings beat expectations, but sales disappointed. Johnson is cautious on its outlook. How it will perform in the future?
$YHOO is reporting today after market close. Nobody cares about this stock.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.